Big pharma, Partnering, Pharma

Merck and Arvinas in therapy alliance using Protac technology

Posted on 09 April 2015

Tags: , ,

Arvinas announced a strategic collaboration with Merck in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.

The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

While the specifics of the financial arrangements were not disclosed, Arvinas will receive an up-front payment and funding to support Merck-related research.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Additionally, Arvinas could earn up to $434 million if all research, development, regulatory and commercial milestone payments are successfully paid for products against all the targets initially selected by Merck, as well as tiered royalties.

Merck may, at its discretion, elect to expand the collaboration to include additional disease targets.

This decision would trigger an additional one-time payment, as well as payment of milestones and royalties on a product-by-product basis.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply